You are here

Buprenorphine For Transdermal Analgesia

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AR42790-1,
Agency Tracking Number: 24817
Amount: $80,225.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1994
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
21-C Olympia Avenue
Woburn, MA 01801
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Larry Nichols
 (617) 938-0938
Business Contact
Phone: () -
Research Institution

We will demonstrate the practical feasibility of transdermal analgesic therapy based onbuprenorphine, a potent opioid already used intravenously and intramuscularly for the relief of moderateto severe pain. Preliminary in vitro experiments have confirmed that buprenorphine can pass throughhuman skin at potentially therapeutic rates. Using BIOTEK's patented DermaPatch transdermal systemit should be possible to develop small analgesic patches based on buprenorphine, one of the most benignof the opioid analgesics. Phase I will prepare candidate formulations, optimize their in vitroperformance using stratum corneum from human breast skin, and test blood levels and skin irritation ofpatches containing the best formulation on rabbits. Successful completion of Phase I will lead to a PhaseII devoted to the documentary, clinical, regulatory and licensing steps required for successfulcommercialization of a new transdermal product.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government